Trending NewsTrending NewsNASDAQ:INCY Incyte (INCY) Stock Price, News & Analysis $124.34 +0.45 (+0.37%) As of 10:54 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Incyte Stock (NASDAQ:INCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Incyte alerts:Sign Up Key Stats Today's Range$122.53▼$124.4250-Day Range$115.65▼$129.9352-Week Range$82.52▼$132.60Volume197,113 shsAverage Volume1.71 million shsMarket Capitalization$25.20 billionP/E Ratio15.84Dividend YieldN/APrice Target$124.15Consensus RatingModerate Buy Company Overview Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for oncology and inflammatory diseases. Founded in 1991 and headquartered in Wilmington, Delaware, the company conducts research in areas including oncology, hematology, immunology and dermatology. Incyte’s commercial portfolio includes Jakafi (ruxolitinib), a treatment for certain myelofibrosis, polycythemia vera and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib) for selected cancers involving abnormal FGFR signaling. The company also markets other therapies, including Minjuvi/Monjuvi (tafasitamab) for certain adults with relapsed or refractory diffuse large B-cell lymphoma, and Zynyz (retifanlimab) for a type of advanced squamous cell carcinoma. Incyte develops medicines independently and through collaborations with pharmaceutical and biotechnology companies. Its products and research activities serve patients and healthcare providers in the United States and international markets, with the company maintaining operations and partnerships across North America, Europe and other regions. Hervé Hoppenot serves as Incyte’s chief executive officer.AI Generated. May Contain Errors. Read More Incyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreINCY MarketRank™: Incyte scored higher than 61% of companies evaluated by MarketBeat, and ranked 357th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingIncyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 1 strong buy rating, 11 buy ratings, 13 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Incyte is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageIncyte has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Incyte's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth200.38% Earnings GrowthEarnings for Incyte are expected to grow by 200.38% in the coming year, from $2.64 to $7.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 15.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 15.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 276.18.Price to Earnings Growth RatioIncyte has a PEG Ratio of 3.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 4.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Incyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.88% of the float of Incyte has been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 7.26.Change versus previous monthShort interest in Incyte has recently increased by 6.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.40 News SentimentIncyte has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Incyte this week, compared to 8 articles on an average week.Search Interest14 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows7 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,361,428.00 in company stock.Percentage Held by Insiders16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Incyte's insider trading history. Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCY Stock News HeadlinesMirum’s Brellovitug Phase 3 Success Signals Transformational Growth1 hour ago | tipranks.comMiniMed appoints Sheila Denton as General Counsel & Corporate Secretary1 hour ago | prnewswire.comA bill in Congress would require the Treasury to reprice America's gold. Here is what it means for your 401k.The US government still values its gold reserves at $42 an ounce, a price set by Congress back in 1973 and never updated. Gold trades above $4,000 today, meaning America's official gold holdings are booked at roughly $11 billion when they're actually worth more than $1 trillion. A bill moving through Congress right now would require the Treasury to reprice America's gold at true market value, and separate proposals would allow the first audit of US gold reserves in over 65 years. The 2026 Gold Guide breaks down what a repricing could mean and how eligible Americans can move savings into physical gold, tax-free and penalty-free.September 28 at 1:00 AM | Monetary Gold (Ad)Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA2 hours ago | marketscreener.comMHC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating2 hours ago | marketscreener.comMMirum and Incyte’s Atebrioz approved for FOP in US2 hours ago | yahoo.comHC Wainwright Forecasts Strong Price Appreciation for Incyte (NASDAQ:INCY) Stock2 hours ago | americanbankingnews.comIncyte: Atebrioz Approval and KRAS Pipeline Upside Drive Buy Rating; Price Target Raised to $1524 hours ago | tipranks.comSee More Headlines INCY Stock Analysis - Frequently Asked Questions How have INCY shares performed this year? Incyte's stock was trading at $98.77 at the beginning of 2026. Since then, INCY stock has increased by 25.4% and is now trading at $123.89. How were Incyte's earnings last quarter? Incyte Corporation (NASDAQ:INCY) released its quarterly earnings data on Tuesday, July, 28th. The biopharmaceutical company reported $3.09 EPS for the quarter, topping analysts' consensus estimates of $2.15 by $0.94. Incyte's quarterly revenue was up 37.7% compared to the same quarter last year. Read the conference call transcript. Who are Incyte's major shareholders? Incyte's top institutional shareholders include BlackRock Inc. (8.90%), Wellington Management Group LLP (1.76%), Legal & General Group Plc (0.79%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.74%). Insiders that own company stock include Pablo J Cagnoni, Mohamed Khairie Issa, Steven H Stein, Patrick A Mayes, Barry P Flannelly, Jonathan Elliott Dickinson, Vijay K Iyengar, Lee Heeson, Michael James Morrissey, Sheila A Denton and Thomas Tray. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings7/28/2026Today9/28/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INCY's financial health is in the Green zone, according to TradeSmith. INCY has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INCY CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,844Year Founded1991Price Target and Rating Average Price Target for Incyte$124.15 High Price Target$155.00 Low Price Target$90.00 Potential Upside/Downside-0.1%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$7.85 Trailing P/E Ratio15.82 Forward P/E Ratio47.06 P/E Growth3.6Net Income$1.29 billion Net Margins27.71% Pretax Margin33.81% Return on Equity29.93% Return on Assets22.88% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.51 Sales & Book Value Annual Sales$5.14 billion Price / Sales4.90 Cash Flow$6.20 per share Price / Cash Flow20.05 Book Value$26.32 per share Price / Book4.72Miscellaneous Outstanding Shares202,700,000Free Float169,861,000Market Cap$25.18 billion OptionableOptionable Beta0.77 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:INCY) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredUnder $5, Is This Nasdaq Early to America's Next Defense Boom?Small drones costing hundreds of dollars can now rival tanks and equipment worth millions, a shift Ukraine has...i2i Marketing Group, LLC | SponsoredHOST Just Closed Its Major Merger!Host Digital Inc (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp on September 17,...Trading Wire | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredA bill in Congress would require the Treasury to reprice America's gold. Here is what it means for your 401k.The US government still values its gold reserves at $42 an ounce, a price set by Congress back in 1973 and nev...Monetary Gold | SponsoredThe Department of War is on a gold mine's filingsOn May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
